Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Janie Earle

Nurse Practitioner, Gerontology Washington, UT Nurse Practitioner

NPI 1720752389 CMS profile 10922409

135 E Antone Way, Washington, UT 84780

Open in the dashboard

General payments

$7,949

10 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Janie Earle of Washington, UT is reported in the CMS Open Payments database as having received $7,949 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2,043 4
2022 General $3,544 4
2021 General $2,363 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janie Earle
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Janie Earle were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Janie Earle Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,363 $133 $44–$396 $132
2022 $3,544 $142 $48–$452 $149
2023 $2,043 $158 $53–$482 $160
2024 $0 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Eisai Inc. $7,949 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Consulting Fee $6,781 8 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,168 2 payments
Products named General payments · program years 2021–2023
  1. Leqembi $2,043 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,240

Median for Nurse Practitioner: 389

Drug cost

$132,174

Median for Nurse Practitioner: $21,885

Branded share of claims

13.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 31 $23,188
Myrbetriq Mirabegron Brand 24 $16,186
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $11,672
Jardiance Empagliflozin Brand 12 $8,566
Januvia Sitagliptin Phosphate Brand 15 $7,695
Symbicort Budesonide/Formoterol Fumarate Brand 16 $3,501
Midodrine Hcl Generic 20 $2,895
Ziprasidone Hcl Generic 24 $2,352
Gabapentin Generic 128 $2,130
Quetiapine Fumarate Generic 140 $1,984

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$490,028

Of which drugs: $369,003

Medicare patients

212

Average age 83

Services billed

1,742

135 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Depression 52%
Alzheimer's or dementia 46%
Chronic kidney disease 39%
Diabetes 31%
Heart failure 31%
Ischemic heart disease 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 41 $41

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record